Skip to main content
logo
Evofem Biosciences, Inc. (EVFM)
OTCMKTS · Delayed Price · Currency is USD
0.0076
+0.00003 (0.40%)
At close: Jul 29, 2026

Evofem Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
20.2420.1819.3618.2216.848.24
Revenue Growth
21.87%4.23%6.29%8.20%104.23%1748.43%
Gross Profit
15.5815.5715.5311.7112.424.19
Operating Income
-3.461.44-7.68-17.85-84.12-166.8
Net Income
-6.160.27-8.9750-78.01-206.24
Earnings Per Share
-0.050.00-0.110.05-167.42-2953.95
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1.620.130.130.082.777.73
Total Debt
52.4654.5545.9743.3771.13115.68
Net Cash (Debt)
-50.84-54.42-45.84-43.3-68.36-107.95
Net Cash Growth
------
Net Cash Per Share
-0.40-0.01-0.57-0.04-146.70-1546.16

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-0.25-1.99-3.89-8.97-70.41-146.67
Capital Expenditures
-0.01-0.01-0.01-0-0.34-2.94
Free Cash Flow
-0.26-2-3.9-8.97-70.75-149.61
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
76.96%77.12%80.20%64.25%73.78%50.81%
Operating Margin
-17.08%7.13%-39.64%-97.96%-499.64%-2023.30%
Pretax Margin
-29.79%1.95%-45.76%290.90%-455.27%-2488.78%
Profit Margin
-30.46%1.36%-46.30%274.43%-463.35%-2501.69%
FCF Margin
-1.27%-9.89%-20.14%-49.25%-420.21%-1814.73%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-4.39-0.03--
PS Ratio
0.050.060.060.070.477.43